Age Related Macular Degeneration Market Size, Share, and Trends Analysis Report

CAGR :  Diagram

Market Size 2023 (Base Year) USD 11.6 Billion
Market Size 2032 (Forecast Year) USD 20.65 Billion
CAGR 6.62%
Forecast Period 2024 - 2032
Historical Period 2018 - 2023

Age Related Macular Degeneration Market Insights

A latest report by Market Research Store estimates that the Global Age Related Macular Degeneration Market was valued at USD 11.6 Billion in 2023 and is expected to reach USD 20.65 Billion by 2032, with a CAGR of 6.62% during the forecast period 2024-2032. The report Age Related Macular Degeneration Market overview, growth factors, restraints, opportunities, segmentation, key developments, competitive landscape, consumer insights, and market growth forecast in terms of value or volume. These structured details offer an all-inclusive market overview, providing valuable insights for investment decisions, business decisions, strategic planning, and competitive analysis.

Age Related Macular Degeneration Market Size

Age Related Macular Degeneration Market: Report Scope

Report Attributes Report Details
Report Name Age Related Macular Degeneration Market
Market Size in 2023 USD 11.6 Billion
Market Forecast in 2032 USD 20.65 Billion
Growth Rate CAGR of 6.62%
Number of Pages 177
Key Companies Covered Valeant Pharmaceuticals International, Inc., Novartis International AG, Ophthotech Corporation, Pfizer Inc., Kubota Pharmaceutical Holdings Co. Ltd, Bayer AG, Adverum Biotechnologies, Inc., Regeneron Pharmaceuticals, Inc., Amgen Inc., Gilead Sciences Inc., Apellis Pharmeceuticals, Inc., F. Hoffmann-La Roche Ltd., Bausch Health Companies Inc., Neurotech Pharmaceuticals Inc., and Alimera Sciences Inc., and Others
Segments Covered By Product Type, By Drug Type, By Route Of Administration, By Age Group Type, By, By And End-User, And By Region
Regions Covered North America, Europe, Asia Pacific (APAC), Latin America, Middle East, and Africa (MEA)
Base Year 2023
Historical Year 2018 to 2023
Forecast Year 2024 to 2032
Customization Scope Avail customized purchase options to meet your exact research needs. Request For Customization

According to the report published by Market Research Store, global demand for the age related macular degeneration market was estimated at approximately USD 8,300 Million in 2019 and is anticipated to generate revenue of around USD 14,100 Million by end of 2026, growing at a CAGR of around 7.8% between 2020 and 2026.

Global Age Related Macular Degeneration Market: Overview

Macular degeneration, ARMD, or AMD are all terms for age-related macular degeneration. AMD is a retinal condition that causes blurring of central vision, which is essential for tasks such as driving, using a keyboard, watching tv, sewing, and reading that include looking straight ahead. The macula, a portion of the retina that helps you to see fine details, is impaired by AMD. AMD is a progressive eye condition that is painless. It is most common in patients over the age of 50.

Wet macular degeneration and dry macular degeneration are the two types of AMD. The first kind of AMD is the more serious of the two. It induces irregular blood flow progression in the affected region of the macula, impairing retinal vision. Though AMD is linked to aging, the study suggests that the disorder may also have a genetic aspect. Scientists from Duke University and other institutions have discovered a close connection between AMD production and the presence of gene variants such as complement factor H. (CFH). Nearly half of the potentially blinding cases of AMD are diagnosed with CFH gene deficiency. Variants of an additional gene, complement factor B, have been discovered to be active in the production of AMD by researchers at the University of Columbia Medical Center and others. A rare variation of these genes, which plays a crucial role in human immune responses, was discovered in about 74 percent of AMD patients surveyed. There is currently no cure for dry AMD; however, existing treatments may help to prolong the onset of vision loss and wet AMD.

Global Age Related Macular Degeneration Market: Growth Factors

Over the projected period, the demand for age-related macular degeneration is predicted to be driven by an increase in the geriatric population. According to the World Population Prospects report from 2017, the global population over 60 years old was 962 million, with a projected increase to about 2.1 billion by 2050. Globally, the population of people aged 60 and over is growing at a higher rate than all other age classes. This population is particularly vulnerable to age-related diseases such as diabetes, renal insufficiency, asthma, and macular degeneration. People between the ages of 50 and 59 have a 2% chance of developing advanced age-related macular degeneration, while those above the age of 75 have a 30% chance. Furthermore, over the projected period, the rising prevalence of age-related macular degeneration is anticipated to accelerate growth. As per the BrightFocus Foundation in January 2019, macular degeneration is the main cause of blindness in the U.S. population over 60 years old, with about 11 million people affected, with the number projected to double to almost 22 million by 2050.

Global Age Related Macular Degeneration Market: Segmentation

Age related macular degeneration market is segmented in terms of product type, drug type, route of administration, age group type, and end-user. Based on the product type, the market is divided into dry AMD and wet AMD. Wet AMD is caused by premature growth of blood vessels under the macula, while dry AMD is caused by the development of deposits called under the retina. Wet AMD has a greater market share than dry AMD due to the higher incidence of wet AMD in the geriatric community. The growing geriatric population around the world is driving up demand for wet macular degeneration treatments. According to a survey by the World Health Organization (WHO), the number of elderly people (those aged 60 and up) is predicted to rise to 21.1 percent by 2050. In 2050, the global population of elderly people is expected to exceed 2 billion. Both of these figures indicate that there will be a strong need for drugs to combat wet macular degeneration in the future. The demand is growing due to technical advances in macular degeneration care and adequate payment conditions. Based on the route of administration, the market is split into intravitreal and intravenous. The intravitreal segment is anticipated to gain market share because targeted drug distribution makes it more competitive. In addition, the majority of anti-VEGF injections are given intravitreal or intraocularly. On the basis of end-user analysis, the market is bifurcated into hospitals & clinics, academic research institutes, and diagnostic centers. In terms of revenue, the most common end-user category is hospitals and clinics. This is due to increased exposure to global trends, increasing disposable incomes, and changing lifestyles, which are among the common reasons for an increase in the number of visits to these institutes, as well as the number of procedures performed. The needed procedures are performed in a sterile environment and do not necessitate a long time of waiting or recovery. Based on age group type, the market is divided between 40 - 50 years, between 50 - 60 years, between 60 - 70 years, and above 70 years. The global population over 60 years old was 962 million in 2017, according to World Population Prospects, and is projected to hit around 2.1 billion by 2050. Globally, the population of people aged 60 and over is growing at a higher rate than all other age classes. This population is particularly vulnerable to age-related diseases such as diabetes, renal insufficiency, asthma, and macular degeneration. People between the ages of 50 and 59 have a 2% chance of developing advanced age-related macular degeneration, while those above the age of 75 have a 30% chance.

Global Age Related Macular Degeneration Market: Regional Analysis

In North America, the aesthetic equipment industry has evolved rapidly over the last two decades. Technological advancements in devices, growing knowledge of cosmetic procedures, rising acceptance of minimally invasive devices, and an increase in the obese population in the area are all projected to positively impact the studied market's development. There were 18.1 million cosmetic operations performed in 2019, up 2% from 2018, including 1.8 million cosmetic surgical procedures and 16.3 million cosmetic minimally medical interventions, according to the data shared by the American Society of Plastic Surgeons. In addition, the region's high concentration of global players, as well as subsequent product releases, play an important role in the region's market development. For example, Essence Group's E.S.I. company, released JOLI360, a revolutionary facial rejuvenation treatment that can calculate three skin factors: hydration, elasticity, and sebum, in June 2020. As a result, the above factors are projected to fuel the demand in North America over the forecast period.

Global Age Related Macular Degeneration Market: Competitive Players

The major players dominating the global age related macular degeneration market in terms of revenue and development are Valeant Pharmaceuticals International, Inc., Novartis International AG, Ophthotech Corporation, Pfizer Inc., Kubota Pharmaceutical Holdings Co. Ltd, Bayer AG, Adverum Biotechnologies, Inc., Regeneron Pharmaceuticals, Inc., Amgen Inc., Gilead Sciences Inc., Apellis Pharmeceuticals, Inc., F. Hoffmann-La Roche Ltd., Bausch Health Companies Inc., Neurotech Pharmaceuticals Inc., and Alimera Sciences Inc., and Others. These international companies have used a number of tactics to create a credible presence in the global economy, including purchasing relationships, shares, arrangements, collaborations, joint ventures, new product launches, revenues, and mergers and acquisitions. In July 2017, Ophthotech Corporation announced that it would develop treatments for a number of orphan ophthalmic diseases based on clinical practice and retina expertise. In December 2016, EyeMedics, LLC and Acucela agreed to collaborate on research and development. In September 2017, F. Hoffmann-La Roche AG announced the first lampalizumab phase III trial for geographic atrophy caused by AMD.

Age Related Macular Degeneration Market: Regional Segment Analysis

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Frequently Asked Questions

These dominant industry players use well planned strategies to occupied highest market share in this market. Some of the top players in [Keyword] business includes. [Company list]

As per [Keyword] market analysis, North America is forecasted to occupied major share in the [Keyword] market.

The statistical data of the dominant industry player of [Keyword] market can be acquired from the company profile segment described in the report. This segment come up with analysis of major player’s in the [Keyword] market, also their last five-year revenue, segmental, product offerings, key strategies adopted and geographical revenue produced.

The report come up with a segment of the [Keyword] market based on Type, Region, and Application, Also offer a determined view on the [Keyword] market.

The report offers a nitty-gritty estimation of the market by providing data on various viewpoints that incorporate, restraints, drivers, and opportunities threats. This data can help in making suitable decisions for stakeholders before investing.

The sample report for [Keyword] market can be received after the apply from the website.

Table Of Content

Inquiry For Buying

Age Related Macular Degeneration

Please fill out the form. We will contact you within 24 hours:
All fields required...

Request Sample

Age Related Macular Degeneration

Please fill out the form. We will contact you within 24 hours:
All fields required...

×

Avail Free PDF Sample Report

This website is secure and your personal details are safe. Privacy Policy

Thank you for contacting us.

Thank you for your interest in our research report.

We will be sending you the sample copy of the report shortly. Meanwhile, if you have any specific research requirement then please let us know. We will be glad to assist you in case you have any additional questions, so feel free to get in touch

Thank you


Warm regards,
Sales | Manager - International Business and partner Relations
Direct line: +1 347 535 0815
Market Research Store
E-mail: sales@MarketResearchStore.com | Web: www.MarketResearchStore.com